Recent developments of interest in cardiovascular medicine
SGLT2 diabetes drug empagliflozin (Jardiance) failed to improve exercise ability over placebo in chronic heart failure patients with or without diabetes in top-line data announced from the phase III trials Emperial-Reduced and Emperial-Preserved. (FiercePharma)
After vernakalant's bad day at the FDA panel that shot down its long-awaited second shot at approval for atrial fibrillation conversion, sponsor Correvio went on the auction block. (Endpoints News)
Absent from icosapent ethyl (Vascepa)'s new indication for cardiovascular risk reduction was the primary prevention group that had been sought after, except diabetes patients with at least two additional risk factors for heart disease. Also, the prescription fish oil is facing litigation over generics starting in January. (Endpoints News)
Hundreds of lawyers attacked a cardiology hospital in Lahore, Pakistan, breaking windows and equipment. Three patients died. (New York Times)
Obesity in kids affects routine blood tests, including lipid levels and inflammatory markers. (Journal of Clinical Endocrinology & Metabolism)
Mendelian randomization isn't the perfect answer to epidemiology's causation problem. Nature has the story.
The Xvivo Heart Preservation System got FDA breakthrough device designation as a cold storage device that perfuses excised donor hearts for preservation prior to transplant, Xvivo Perfusion announced.
Low income and high stress at work may explain up to a third of excess cardiovascular disease mortality and morbidity among young and middle-age adults, a Danish study suggested. (European Heart Journal)
A genetic variant that causes hereditary transthyretin amyloid cardiomyopathy is underdiagnosed in individuals of African descent. (AJMC Managed Markets Network)
Could the next generation of pacemakers be made from fat? Researchers reported making adipogenic mesenchymal stem cells into cardiac progenitor cells programmed to function as a sinoatrial node. (Journal of Molecular and Cellular Cardiology)
Hearing and poor mobility should be considered along with other factors that impact mortality after a heart attack, researchers reported in the Annals of Internal Medicine.
Antibodies against RNA polymerase III can be a red herring in viral myocarditis, researchers reported in the Annals of Internal Medicine.
Sanofi is ending its cardiovascular and diabetes research and development in favor of immunology and vaccines. (MobiHealthNews)
Read the original article on Medpage Today: Jardiance Flops in HF Trials; Mob of Lawyers Attacks Hospital; Pacemaker From Fat?